Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2477631 | 0.77 | IDO1 (0.42) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL9933773 | 0.73 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1ANPEP | |
| SCHEMBL19284176 | 0.70 | — | — | |
| SCHEMBL17956326 | 0.70 | IDO1 (0.53) | IDO1CYP19A1ADRA2ASIGMAR1ANPEP | |
| SCHEMBL835059 | 0.69 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL385635 | 0.69 | IDO1 (0.41) | IDO1ANPEPCA1CA2MTNR1A | |
| SCHEMBL1800050 | 0.69 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL2974609 | 0.69 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL22052056 | 0.69 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL29593942 | 0.69 | HTR2A (0.52) | IDO1CYP19A1ADRA2APLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020061839-A1 | Serine peptidase modulators | SCHARPE SIMON LODEWIJK (BE) | 2002-05-23 | — | — | US | claimed |
| JP-2002506075-A | — | — | 2002-02-26 | — | — | JP | claimed |
| EP-1062222-A1 | SERINE PEPTIDASE MODULATORS | Fondatech Benelux N.V. (BE) | 2000-12-27 | — | — | EP | claimed |
| WO-1999046272-A1 | SERINE PEPTIDASE MODULATORS | FONDATECH BENELUX N.V. (BE) | 1999-09-16 | — | — | WO | claimed |
| WO-2019135600-A1 | NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME | 기초과학연구원 | 2019-07-11 | — | — | WO | disclosed |
| US-8143304-B2 | (3-amino-1,2,3,4-tetrahydro-9 H-carbazol-9-yl)-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2051962-B1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-2316824-A1 | (3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates | Actelion Pharmaceuticals Ltd. (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-7858349-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010127381-A1 | DIAGNOSIS, MONITORING, PROGNOSIS, PREVENTION AND TREATMENT OF ANEURYSMS | JAMES COOK UNIVERSITY (AU) | 2010-11-11 | — | — | WO | disclosed |
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-29 | — | — | US | disclosed |
| EP-2051962-A1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-20090088454-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-04-02 | — | — | US | disclosed |
| US-7427496-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2008-09-23 | — | — | US | disclosed |
| WO-2008017989-A1 | (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-14 | — | — | WO | disclosed |
| US-20060183772-A1 | To inhibit tumor growth in an animal; to induce apoptosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-08-17 | — | — | US | disclosed |
| US-20020061839-A1 | Serine peptidase modulators | SCHARPE SIMON LODEWIJK (BE) | 2002-05-23 | — | — | US | disclosed |
| EP-1062222-A1 | SERINE PEPTIDASE MODULATORS | Fondatech Benelux N.V. (BE) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046272-A1 | SERINE PEPTIDASE MODULATORS | FONDATECH BENELUX N.V. (BE) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061839-A1 | Serine peptidase modulators | FAP, CTSC, DPP4 | IDO1 541/4885CYP19A1 4381/4885ADRA2A 3520/4885 |
| US-20100190830-A1 | (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives | PTGDR, PTGER1, PTGIR | IDO1 633/4885CYP19A1 715/4885ADRA2A 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.